Evotec AG ( (EVO) ) has issued an announcement. On August 13, 2025, Evotec AG announced its financial results for the first half of 2025, highlighting a strategic shift towards sustainable profitable growth. The company reported a 5% decrease in group revenues to €371.2 million compared to the same period in 2024, primarily due to a soft demand in the Discovery & Preclinical Development segment. However, the Just – Evotec Biologics segment exceeded expectations with a 16% increase in revenues. Significant progress was made in collaborations with Bristol Myers Squibb, resulting in substantial payments, and a grant was awarded by The Gates Foundation for tuberculosis treatment development. Additionally, Evotec announced a potential sale of its Just – Evotec Biologics EU segment to Sandoz AG, expected to close in the fourth quarter, which could impact its operational focus and market positioning. The most recent analyst rating on (EVO) stock is a Sell with a $3.00 price target.

Spark’s Take on EVO Stock

According to Spark, TipRanks’ AI Analyst, EVO is a Neutral. Evotec’s overall score is driven by financial challenges, including profitability and cash flow issues, which are the most significant factors. Technical analysis and valuation further highlight concerns. While the earnings call provides some positive insights, overall financial struggles and valuation pressures weigh on the stock.

More about Evotec AG

Evotec AG is a biotechnology company that specializes in drug discovery and development solutions. The company focuses on providing integrated services and solutions for pharmaceutical and biotechnology companies, with a particular emphasis on discovery and preclinical development. Evotec operates in various segments, including Discovery & Preclinical Development and Just – Evotec Biologics, aiming to drive innovation in the life sciences industry.

Average Trading Volume: 108,698

Technical Sentiment Signal: Strong Sell

Current Market Cap: $1.36B

Evotec AG Reports H1 2025 Results

Evotec AG announced that its first‑half 2025 revenues fell 5% to €371.2 million, driven mainly by softer demand in its Discovery & Preclinical Development segment. The company’s Just – Evotec Biologics division, however, posted a 16% revenue increase. Significant progress was made in collaborations with Bristol Myers Squibb, and a grant was awarded by the Gates Foundation for tuberculosis treatment research. Evotec also disclosed a potential sale of its Just – Evotec Biologics EU segment to Sandoz AG, expected to close in Q4, and noted a current market cap of $1.36 billion with a strong sell technical sentiment.